- Conditions
- Breast Cancer, Hereditary Breast/Ovarian Cancer (brca1, brca2)
- Interventions
- counseling intervention, educational intervention, survey administration, psychosocial assessment and care, supportive care
- Other · Behavioral
- Lead sponsor
- Georgetown University
- Other
- Eligibility
- 8 Years to 120 Years · Female only
- Enrollment
- 245 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 2
- States / cities
- Washington D.C., District of Columbia • Boston, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 625–648
of 10,802
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Congenital Adrenal Hyperplasia
- Interventions
- Chronocort®, Standard Care
- Drug
- Lead sponsor
- Neurocrine UK Limited
- Industry
- Eligibility
- 16 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Morehead City, North Carolina
- Conditions
- Hemophilia B with Inhibitor, Hemophilia B
- Interventions
- SerpinPC
- Drug
- Lead sponsor
- ApcinteX Ltd
- Industry
- Eligibility
- 12 Years to 65 Years · Male only
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 3
- States / cities
- Aurora, Colorado • Tampa, Florida • Greenville, North Carolina
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Interventions
- decitabine, romidepsin
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2005
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Down Syndrome
- Interventions
- Promoting Health through Parent Empowerment and the Activation of Routines, Enhanced Usual Care
- Behavioral
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 12 Months and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Skin Laxity, Muscle Contracture
- Interventions
- DMA treatment
- Device
- Lead sponsor
- Lumenis Be Ltd.
- Industry
- Eligibility
- 25 Years to 45 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Charlotte, North Carolina
- Conditions
- ALK Positive, Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, ROS1 Gene Rearrangement, Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IV Lung Non-Small Cell Cancer AJCC v7
- Interventions
- Ceritinib, Everolimus, Laboratory Biomarker Analysis, Pharmacological Study
- Drug · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Retinitis Pigmentosa (RP)
- Interventions
- human retinal progenitor cells
- Biological
- Lead sponsor
- jCyte, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 2
- States / cities
- Irvine, California • Los Angeles, California
- Conditions
- Late Infantile Neuronal Ceroid Lipofuscinosis, Batten Disease
- Interventions
- Group 1
- Other
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 2 Years to 8 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2015
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Spine Deformity
- Interventions
- OrthoPAT, Constavac
- Device
- Lead sponsor
- Hospital for Special Surgery, New York
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2016
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Hemoglobinopathies, Hemolysis, Iron Deficiency and Overload, Anemias
- Interventions
- Not listed
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 1 Year and older
- Enrollment
- 334 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2017
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Retinitis Pigmentosa
- Interventions
- Transcorneal Electrical Stimulation using Okustim device
- Device
- Lead sponsor
- Wills Eye
- Other
- Eligibility
- 22 Years to 80 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Prader-Willi Syndrome
- Interventions
- Interview
- Other
- Lead sponsor
- Soleno Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 59 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Plymouth, Massachusetts
- Conditions
- Fuchs' Corneal Endothelial Dystrophy
- Interventions
- NCI Insertion, Standard Forceps Insertion
- Device · Procedure
- Lead sponsor
- Legacy Health System
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Hermansky-Pudlak Syndrome (HPS), Pulmonary Fibrosis, Oculocutaneous Albinism, Platelet Storage Pool Deficiency, Metabolic Disease
- Interventions
- Losartan, Zileuton, N-Acetylcysteine, Pravastatin, Erythromycin
- Drug
- Lead sponsor
- National Human Genome Research Institute (NHGRI)
- NIH
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- GM1 Gangliosidosis
- Interventions
- Not listed
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- Not listed
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 2
- States / cities
- Oakland, California • Philadelphia, Pennsylvania
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Interventions
- sargramostim
- Biological
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 5 Years to 60 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Andersen-Tawil Syndrome
- Interventions
- Potassium, Acetazolamide
- Dietary Supplement · Drug
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 10 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Hemophilia A
- Interventions
- Antihemophilic factor, recombinant, manufactured protein-free
- Drug
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Eligibility
- 10 Years and older · Male only
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2004
- U.S. locations
- 11
- States / cities
- Aurora, Colorado • Atlanta, Georgia • Peoria, Illinois + 7 more
- Conditions
- Osteogenesis Imperfecta
- Interventions
- Denosumab
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 153 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2022
- U.S. locations
- 13
- States / cities
- Los Angeles, California • Torrance, California • Aurora, Colorado + 10 more
- Conditions
- Pompe Disease (Late-onset)
- Interventions
- Cipaglucosidase Alfa, Miglustat
- Biological · Drug
- Lead sponsor
- Amicus Therapeutics
- Industry
- Eligibility
- 0 Years to 17 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 9
- States / cities
- Gainesville, Florida • Jacksonville, Florida • Atlanta, Georgia + 6 more
- Conditions
- Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, Dystrophinopathy, Dystrophinopathy Symptomatic Female Carrier, Dystrophinopathy Female Carrier
- Interventions
- Not listed
- Lead sponsor
- The Duchenne Registry
- Other
- Eligibility
- Not listed
- Enrollment
- 10,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2047
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Infant, Premature, Diseases, Bronchopulmonary Dysplasia, Respiratory Distress Syndrome
- Interventions
- Non-invasive forced airway oscillometry
- Device
- Lead sponsor
- Winston Manimtim
- Other
- Eligibility
- Not listed
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- Kansas City, Missouri
- Conditions
- Epidermolysis Bullosa
- Interventions
- Thymoglobulin, Cyclophosphamide, Fludarabine, Total Body Irradiation, Bone marrow infusion, Tacrolimus, Mycophenolate Mofetil, Donor mesenchymal stem cell infusions, Busulfan
- Drug · Radiation · Procedure + 1 more
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- Up to 25 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota